-
1
-
-
64649104158
-
Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus
-
DeFronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-795.
-
(2009)
Diabetes
, vol.58
, pp. 773-795
-
-
DeFronzo, R.A.1
-
2
-
-
84864285795
-
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
-
Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1577-1596.
-
(2012)
Diabetes Care
, vol.35
, pp. 1577-1596
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
-
3
-
-
79954607388
-
Self-reported experience of hypoglycemia among adults with type 2 diabetes mellitus (Exhype)
-
Pettersson B, Rosenqvist U, Deleskog A, Journath G, Wändell P. Self-reported experience of hypoglycemia among adults with type 2 diabetes mellitus (Exhype). Diabetes Res Clin Pract 2011; 92: 19-25.
-
(2011)
Diabetes Res Clin Pract
, vol.92
, pp. 19-25
-
-
Pettersson, B.1
Rosenqvist, U.2
Deleskog, A.3
Journath, G.4
Wändell, P.5
-
4
-
-
79959390444
-
QT measurement and heart rate correction during hypoglycemia: is there a bias?
-
Christensen TF, Randløv J, Kristensen LE, Eldrup E, Hejlesen OK, Struijk JJ. QT measurement and heart rate correction during hypoglycemia: is there a bias? Cardiol Res Pract 2010; 2010: 961290.
-
(2010)
Cardiol Res Pract
, vol.2010
, pp. 961290
-
-
Christensen, T.F.1
Randløv, J.2
Kristensen, L.E.3
Eldrup, E.4
Hejlesen, O.K.5
Struijk, J.J.6
-
5
-
-
0031793981
-
Hypoglycaemia leads to an increased QT interval in normal men
-
Eckert B, Agardh CD. Hypoglycaemia leads to an increased QT interval in normal men. Clin Physiol 1998; 18: 570-575.
-
(1998)
Clin Physiol
, vol.18
, pp. 570-575
-
-
Eckert, B.1
Agardh, C.D.2
-
6
-
-
0032424866
-
Electrocardiographic changes during insulin-induced hypoglycemia in healthy subjects
-
Meinhold J, Heise T, Rave K, Heinemann L. Electrocardiographic changes during insulin-induced hypoglycemia in healthy subjects. Horm Metab Res 1998; 30: 694-697.
-
(1998)
Horm Metab Res
, vol.30
, pp. 694-697
-
-
Meinhold, J.1
Heise, T.2
Rave, K.3
Heinemann, L.4
-
7
-
-
79956095353
-
Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes
-
Johnston SS, Conner C, Aagren M, Smith DM, Bouchard J, Brett J. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care 2011; 34: 1164-1170.
-
(2011)
Diabetes Care
, vol.34
, pp. 1164-1170
-
-
Johnston, S.S.1
Conner, C.2
Aagren, M.3
Smith, D.M.4
Bouchard, J.5
Brett, J.6
-
8
-
-
79251567403
-
Serious cardiovascular outcomes in diabetes: the role of hypoglycemia
-
Yakubovich N, Gerstein HC. Serious cardiovascular outcomes in diabetes: the role of hypoglycemia. Circulation 2011; 123: 342-348.
-
(2011)
Circulation
, vol.123
, pp. 342-348
-
-
Yakubovich, N.1
Gerstein, H.C.2
-
9
-
-
80054967262
-
Death during intensive glycemic therapy of diabetes: mechanisms and implications
-
Cryer PE. Death during intensive glycemic therapy of diabetes: mechanisms and implications. Am J Med 2011; 124: 993-996.
-
(2011)
Am J Med
, vol.124
, pp. 993-996
-
-
Cryer, P.E.1
-
10
-
-
82455210942
-
Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells
-
Leech CA, Dzhura I, Chepurny OG et al. Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells. Prog Biophys Mol Biol 2011; 104: 236-247.
-
(2011)
Prog Biophys Mol Biol
, vol.104
, pp. 236-247
-
-
Leech, C.A.1
Dzhura, I.2
Chepurny, O.G.3
-
11
-
-
0036307610
-
The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects
-
Hui H, Farilla L, Merkel P, Perfetti R. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol 2002; 146: 863-869.
-
(2002)
Eur J Endocrinol
, vol.146
, pp. 863-869
-
-
Hui, H.1
Farilla, L.2
Merkel, P.3
Perfetti, R.4
-
12
-
-
34248223285
-
Biology of incretins: GLP-1 and GIP
-
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157.
-
(2007)
Gastroenterology
, vol.132
, pp. 2131-2157
-
-
Baggio, L.L.1
Drucker, D.J.2
-
13
-
-
58149090676
-
The role of incretins in glucose homeostasis and diabetes treatment
-
Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008; 60: 470-512.
-
(2008)
Pharmacol Rev
, vol.60
, pp. 470-512
-
-
Kim, W.1
Egan, J.M.2
-
14
-
-
79959778328
-
Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability
-
Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care 2011; 34(Suppl 2): S279-S284.
-
(2011)
Diabetes Care
, vol.34
, Issue.SUPPL 2
-
-
Garber, A.J.1
-
15
-
-
77950827693
-
Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes
-
Apovian CM, Bergenstal RM, Cuddihy RM et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med 2010; 123: 468.e9-468.e17.
-
(2010)
Am J Med
, vol.123
-
-
Apovian, C.M.1
Bergenstal, R.M.2
Cuddihy, R.M.3
-
16
-
-
77955573674
-
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
-
Bergenstal RM, Wysham C, MacConell L et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376: 431-439.
-
(2010)
Lancet
, vol.376
, pp. 431-439
-
-
Bergenstal, R.M.1
Wysham, C.2
MacConell, L.3
-
17
-
-
79955661908
-
DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes
-
Blevins T, Pullman J, Malloy J et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 1301-1310.
-
(2011)
J Clin Endocrinol Metab
, vol.96
, pp. 1301-1310
-
-
Blevins, T.1
Pullman, J.2
Malloy, J.3
-
18
-
-
77953859640
-
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
-
Diamant M, Van Gaal L, Stranks S et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375: 2234-2243.
-
(2010)
Lancet
, vol.375
, pp. 2234-2243
-
-
Diamant, M.1
Van Gaal, L.2
Stranks, S.3
-
19
-
-
53249142132
-
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
-
Drucker DJ, Buse JB, Taylor K et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-1250.
-
(2008)
Lancet
, vol.372
, pp. 1240-1250
-
-
Drucker, D.J.1
Buse, J.B.2
Taylor, K.3
-
20
-
-
79951906623
-
Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2years as monotherapy compared with glimepiride in patients with type 2 diabetes
-
Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 348-356.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 348-356
-
-
Garber, A.1
Henry, R.R.2
Ratner, R.3
Hale, P.4
Chang, C.T.5
Bode, B.6
-
21
-
-
77958540163
-
A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin
-
Liutkus J, Rosas Guzman J, Norwood P et al. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Diabetes Obes Metab 2010; 12: 1058-1065.
-
(2010)
Diabetes Obes Metab
, vol.12
, pp. 1058-1065
-
-
Liutkus, J.1
Rosas Guzman, J.2
Norwood, P.3
-
22
-
-
62449169287
-
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study
-
Nauck M, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32: 84-90.
-
(2009)
Diabetes Care
, vol.32
, pp. 84-90
-
-
Nauck, M.1
Frid, A.2
Hermansen, K.3
-
23
-
-
69949117621
-
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
-
Russell-Jones D, Vaag A, Schmitz O et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 2046-2055.
-
(2009)
Diabetologia
, vol.52
, pp. 2046-2055
-
-
Russell-Jones, D.1
Vaag, A.2
Schmitz, O.3
-
25
-
-
0018888159
-
Insulinotropic factors of the gut-the broadening incretin concept
-
Creutzfeldt W. Insulinotropic factors of the gut-the broadening incretin concept. Gastroenterology 1980; 78: 1631-1632.
-
(1980)
Gastroenterology
, vol.78
, pp. 1631-1632
-
-
Creutzfeldt, W.1
-
26
-
-
0021864130
-
New developments in the incretin concept
-
Creutzfeldt W, Ebert R. New developments in the incretin concept. Diabetologia 1985; 28: 565-573.
-
(1985)
Diabetologia
, vol.28
, pp. 565-573
-
-
Creutzfeldt, W.1
Ebert, R.2
-
27
-
-
0026080393
-
GLP-1 and GLP-1(7-36) amide: influences on basal and stimulated insulin and glucagon secretion in the mouse
-
Fridolf T, Böttcher G, Sundler F, Ahrén B. GLP-1 and GLP-1(7-36) amide: influences on basal and stimulated insulin and glucagon secretion in the mouse. Pancreas 1991; 6: 208-215.
-
(1991)
Pancreas
, vol.6
, pp. 208-215
-
-
Fridolf, T.1
Böttcher, G.2
Sundler, F.3
Ahrén, B.4
-
28
-
-
0027523613
-
Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas
-
Göke R, Wagner B, Fehmann HC, Göke B. Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas. Res Exp Med (Berl) 1993; 193: 97-103.
-
(1993)
Res Exp Med (Berl)
, vol.193
, pp. 97-103
-
-
Göke, R.1
Wagner, B.2
Fehmann, H.C.3
Göke, B.4
-
29
-
-
0031724691
-
Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure
-
Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 1998; 21: 1925-1931.
-
(1998)
Diabetes Care
, vol.21
, pp. 1925-1931
-
-
Nauck, M.A.1
Sauerwald, A.2
Ritzel, R.3
Holst, J.J.4
Schmiegel, W.5
-
30
-
-
0028904931
-
Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects
-
Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol 1995; 32: 13-16.
-
(1995)
Acta Diabetol
, vol.32
, pp. 13-16
-
-
Qualmann, C.1
Nauck, M.A.2
Holst, J.J.3
Orskov, C.4
Creutzfeldt, W.5
-
31
-
-
4344713643
-
Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia
-
Degn KB, Brock B, Juhl CB et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004; 53: 2397-2403.
-
(2004)
Diabetes
, vol.53
, pp. 2397-2403
-
-
Degn, K.B.1
Brock, B.2
Juhl, C.B.3
-
32
-
-
0034602252
-
Sustained expression of exendin-4 does not perturb glucose homeostasis, β-cell mass, or food intake in metallothionein-preproexendin transgenic mice
-
Baggio L, Adatia F, Bock T, Brubaker PL, Drucker DJ. Sustained expression of exendin-4 does not perturb glucose homeostasis, β-cell mass, or food intake in metallothionein-preproexendin transgenic mice. J Biol Chem 2000; 275: 34471-34477.
-
(2000)
J Biol Chem
, vol.275
, pp. 34471-34477
-
-
Baggio, L.1
Adatia, F.2
Bock, T.3
Brubaker, P.L.4
Drucker, D.J.5
-
33
-
-
0028058718
-
Incretin hormones regulate glucose-dependent insulin secretion in RIN 1046-38 cells: mechanisms of action
-
Montrose-Rafizadeh C, Egan JM, Roth J. Incretin hormones regulate glucose-dependent insulin secretion in RIN 1046-38 cells: mechanisms of action. Endocrinology 1994; 135: 589-594.
-
(1994)
Endocrinology
, vol.135
, pp. 589-594
-
-
Montrose-Rafizadeh, C.1
Egan, J.M.2
Roth, J.3
-
34
-
-
0036965113
-
The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes
-
Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002; 87: 1282-1290.
-
(2002)
J Clin Endocrinol Metab
, vol.87
, pp. 1282-1290
-
-
Egan, J.M.1
Clocquet, A.R.2
Elahi, D.3
-
35
-
-
56549107405
-
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
-
Linnebjerg H, Park S, Kothare PA et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 2008; 151: 123-129.
-
(2008)
Regul Pept
, vol.151
, pp. 123-129
-
-
Linnebjerg, H.1
Park, S.2
Kothare, P.A.3
-
36
-
-
84859013614
-
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study
-
Russell-Jones D, Cuddihy RM, Hanefeld M et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012; 35: 252-258.
-
(2012)
Diabetes Care
, vol.35
, pp. 252-258
-
-
Russell-Jones, D.1
Cuddihy, R.M.2
Hanefeld, M.3
-
37
-
-
34249869806
-
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
-
Vilsbøll T, Zdravkovic M, Le-Thi T et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30: 1608-1610.
-
(2007)
Diabetes Care
, vol.30
, pp. 1608-1610
-
-
Vilsbøll, T.1
Zdravkovic, M.2
Le-Thi, T.3
-
38
-
-
18144401971
-
Effects of exenatide (exendin-4) on glycemic control and weight over 30weeks in metformin-treated patients with type 2 diabetes
-
DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100.
-
(2005)
Diabetes Care
, vol.28
, pp. 1092-1100
-
-
DeFronzo, R.A.1
Ratner, R.E.2
Han, J.3
Kim, D.D.4
Fineman, M.S.5
Baron, A.D.6
-
39
-
-
51549095571
-
Efficacy and tolerability of exenatide monotherapy over 24weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study
-
Moretto TJ, Milton DR, Ridge TD et al. Efficacy and tolerability of exenatide monotherapy over 24weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008; 30: 1448-1460.
-
(2008)
Clin Ther
, vol.30
, pp. 1448-1460
-
-
Moretto, T.J.1
Milton, D.R.2
Ridge, T.D.3
-
40
-
-
34247259577
-
The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial
-
Zinman B, Hoogwerf BJ, Durán García S et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007; 146: 477-485.
-
(2007)
Ann Intern Med
, vol.146
, pp. 477-485
-
-
Zinman, B.1
Hoogwerf, B.J.2
Durán García, S.3
-
41
-
-
79551615182
-
Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial
-
Buse JB, Bergenstal RM, Glass LC et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011; 154: 103-112.
-
(2011)
Ann Intern Med
, vol.154
, pp. 103-112
-
-
Buse, J.B.1
Bergenstal, R.M.2
Glass, L.C.3
-
42
-
-
84862302997
-
Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised trial
-
Gallwitz B, Guzman J, Dotta F et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised trial. Lancet 2012; 379: 2270-2278.
-
(2012)
Lancet
, vol.379
, pp. 2270-2278
-
-
Gallwitz, B.1
Guzman, J.2
Dotta, F.3
-
43
-
-
84859879074
-
Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of exenatide twice-daily
-
Pencek R, Brunell SC, Li Y, Hoogwerf BJ, Malone J. Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of exenatide twice-daily. Endocr Pract 2012; 18: 227-237.
-
(2012)
Endocr Pract
, vol.18
, pp. 227-237
-
-
Pencek, R.1
Brunell, S.C.2
Li, Y.3
Hoogwerf, B.J.4
Malone, J.5
-
44
-
-
84857385645
-
Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomized, open-label study
-
Buse JB, Nauck M, Forst T et al. Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomized, open-label study. Diabetologia 2011; 54: S38.
-
(2011)
Diabetologia
, vol.54
-
-
Buse, J.B.1
Nauck, M.2
Forst, T.3
-
45
-
-
77953103244
-
Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes
-
Blevins T, Han J, Nicewarner D, Chen S, Oliveira JH, Aronoff S. Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes. Postgrad Med 2010; 122: 118-128.
-
(2010)
Postgrad Med
, vol.122
, pp. 118-128
-
-
Blevins, T.1
Han, J.2
Nicewarner, D.3
Chen, S.4
Oliveira, J.H.5
Aronoff, S.6
-
46
-
-
66149151676
-
GLUT2 mutations, translocation, and receptor function in diet sugar managing
-
Leturque A, Brot-Laroche E, Le Gall M. GLUT2 mutations, translocation, and receptor function in diet sugar managing. Am J Physiol Endocrinol Metab 2009; 296: E985-E992.
-
(2009)
Am J Physiol Endocrinol Metab
, vol.296
-
-
Leturque, A.1
Brot-Laroche, E.2
Le Gall, M.3
-
47
-
-
0028859374
-
Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression
-
De Vos A, Heimberg H, Quartier E et al. Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression. J Clin Invest 1995; 96: 2489-2495.
-
(1995)
J Clin Invest
, vol.96
, pp. 2489-2495
-
-
De Vos, A.1
Heimberg, H.2
Quartier, E.3
-
48
-
-
33847617011
-
Mechanisms of action of glucagon-like peptide 1 in the pancreas
-
Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007; 113: 546-593.
-
(2007)
Pharmacol Ther
, vol.113
, pp. 546-593
-
-
Doyle, M.E.1
Egan, J.M.2
-
49
-
-
10644293820
-
Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential
-
Gromada J, Brock B, Schmitz O, Rorsman P. Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential. Basic Clin Pharmacol Toxicol 2004; 95: 252-262.
-
(2004)
Basic Clin Pharmacol Toxicol
, vol.95
, pp. 252-262
-
-
Gromada, J.1
Brock, B.2
Schmitz, O.3
Rorsman, P.4
-
50
-
-
0032500529
-
Mechanism of cloned ATP-sensitive potassium channel activation by oleoyl-CoA
-
Gribble FM, Proks P, Corkey BE, Ashcroft FM. Mechanism of cloned ATP-sensitive potassium channel activation by oleoyl-CoA. J Biol Chem 1998; 273: 26383-26387.
-
(1998)
J Biol Chem
, vol.273
, pp. 26383-26387
-
-
Gribble, F.M.1
Proks, P.2
Corkey, B.E.3
Ashcroft, F.M.4
-
51
-
-
0033623178
-
KATP channels gated by intracellular nucleotides and phospholipids
-
Baukrowitz T, Fakler B. KATP channels gated by intracellular nucleotides and phospholipids. Eur J Biochem 2000; 267: 5842-5848.
-
(2000)
Eur J Biochem
, vol.267
, pp. 5842-5848
-
-
Baukrowitz, T.1
Fakler, B.2
-
52
-
-
0033556082
-
Molecular mechanisms and regulation of insulin exocytosis as a paradigm of endocrine secretion
-
Lang J. Molecular mechanisms and regulation of insulin exocytosis as a paradigm of endocrine secretion. Eur J Biochem 1999; 259: 3-17.
-
(1999)
Eur J Biochem
, vol.259
, pp. 3-17
-
-
Lang, J.1
-
53
-
-
0042879951
-
Insulin granule dynamics in pancreatic β cells
-
Rorsman P, Renström E. Insulin granule dynamics in pancreatic β cells. Diabetologia 2003; 46: 1029-1045.
-
(2003)
Diabetologia
, vol.46
, pp. 1029-1045
-
-
Rorsman, P.1
Renström, E.2
-
54
-
-
0034410505
-
The cell physiology of biphasic insulin secretion
-
Rorsman P, Eliasson L, Renström E, Gromada J, Barg S, Gopel S. The cell physiology of biphasic insulin secretion. News Physiol Sci 2000; 15: 72-77.
-
(2000)
News Physiol Sci
, vol.15
, pp. 72-77
-
-
Rorsman, P.1
Eliasson, L.2
Renström, E.3
Gromada, J.4
Barg, S.5
Gopel, S.6
-
55
-
-
80051558072
-
TRP channel trafficking
-
Liedtke WB, Heller S, eds. Frontiers in Neuroscience. Boca Raton, FL: CRC Press, Chapter 23.
-
Planells-Cases R, Ferrer-Montiel A. TRP channel trafficking. In: Liedtke WB, Heller S, eds. Source TRP Ion Channel Function in Sensory Transduction and Cellular Signaling Cascades. Frontiers in Neuroscience. Boca Raton, FL: CRC Press, 2007; Chapter 23.
-
(2007)
Source TRP Ion Channel Function in Sensory Transduction and Cellular Signaling Cascades
-
-
Planells-Cases, R.1
Ferrer-Montiel, A.2
-
56
-
-
0036310678
-
2+ channels accounts for first-phase insulin secretion in mouse β cells
-
2+ channels accounts for first-phase insulin secretion in mouse β cells. Diabetes 2002; 51(Suppl 1): S74-S82.
-
(2002)
Diabetes
, vol.51
, Issue.SUPPL 1
-
-
Barg, S.1
Eliasson, L.2
Renström, E.3
Rorsman, P.4
-
57
-
-
9444238518
-
Stimulation of insulin release by glucose is associated with an increase in the number of docked granules in the β cells of rat pancreatic islets
-
Straub SG, Shanmugam G, Sharp GW. Stimulation of insulin release by glucose is associated with an increase in the number of docked granules in the β cells of rat pancreatic islets. Diabetes 2004; 53: 3179-3183.
-
(2004)
Diabetes
, vol.53
, pp. 3179-3183
-
-
Straub, S.G.1
Shanmugam, G.2
Sharp, G.W.3
-
58
-
-
66849115296
-
Mechanisms of biphasic insulin-granule exocytosis-roles of the cytoskeleton, small GTPases and SNARE proteins
-
Wang Z, Thurmond DC. Mechanisms of biphasic insulin-granule exocytosis-roles of the cytoskeleton, small GTPases and SNARE proteins. J Cell Sci 2009; 122: 893-903.
-
(2009)
J Cell Sci
, vol.122
, pp. 893-903
-
-
Wang, Z.1
Thurmond, D.C.2
-
60
-
-
0036310679
-
Triggering and augmentation mechanisms, granule pools, and biphasic insulin secretion
-
Bratanova-Tochkova TK, Cheng H, Daniel S et al. Triggering and augmentation mechanisms, granule pools, and biphasic insulin secretion. Diabetes 2002; 51(Suppl 1): S83-S90.
-
(2002)
Diabetes
, vol.51
, Issue.SUPPL 1
-
-
Bratanova-Tochkova, T.K.1
Cheng, H.2
Daniel, S.3
-
61
-
-
0036720536
-
Ion channels in secretory granules of the pancreas and their role in exocytosis and release of secretory proteins
-
Thevenod F. Ion channels in secretory granules of the pancreas and their role in exocytosis and release of secretory proteins. Am J Physiol Cell Physiol 2002; 283: C651-C672.
-
(2002)
Am J Physiol Cell Physiol
, vol.283
-
-
Thevenod, F.1
-
62
-
-
70349632869
-
Suppression of sulfonylurea- and glucose-induced insulin secretion in vitro and in vivo in mice lacking the chloride transport protein ClC-3
-
Li DQ, Jing X, Salehi A et al. Suppression of sulfonylurea- and glucose-induced insulin secretion in vitro and in vivo in mice lacking the chloride transport protein ClC-3. Cell Metab 2009; 10: 309-315.
-
(2009)
Cell Metab
, vol.10
, pp. 309-315
-
-
Li, D.Q.1
Jing, X.2
Salehi, A.3
-
63
-
-
0028358092
-
The insulin gene contains multiple transcriptional elements that respond to glucose
-
German MS, Wang J. The insulin gene contains multiple transcriptional elements that respond to glucose. Mol Cell Biol 1994; 14: 4067-4075.
-
(1994)
Mol Cell Biol
, vol.14
, pp. 4067-4075
-
-
German, M.S.1
Wang, J.2
-
64
-
-
0142149134
-
Glucose-induced translational control of proinsulin biosynthesis is proportional to preproinsulin mRNA levels in islet β cells but not regulated via a positive feedback of secreted insulin
-
Wicksteed B, Alarcon C, Briaud I, Lingohr MK, Rhodes CJ. Glucose-induced translational control of proinsulin biosynthesis is proportional to preproinsulin mRNA levels in islet β cells but not regulated via a positive feedback of secreted insulin. J Biol Chem 2003; 278: 42080-42090.
-
(2003)
J Biol Chem
, vol.278
, pp. 42080-42090
-
-
Wicksteed, B.1
Alarcon, C.2
Briaud, I.3
Lingohr, M.K.4
Rhodes, C.J.5
-
65
-
-
0036894315
-
The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion
-
MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 2002; 51(Suppl 3): S434-S442.
-
(2002)
Diabetes
, vol.51
, Issue.SUPPL 3
-
-
MacDonald, P.E.1
El-Kholy, W.2
Riedel, M.J.3
Salapatek, A.M.4
Light, P.E.5
Wheeler, M.B.6
-
66
-
-
45549098329
-
Glucose-induced cyclic AMP oscillations regulate pulsatile insulin secretion
-
Dyachok O, Idevall-Hagren O, Sågetorp J et al. Glucose-induced cyclic AMP oscillations regulate pulsatile insulin secretion. Cell Metab 2008; 8: 26-37.
-
(2008)
Cell Metab
, vol.8
, pp. 26-37
-
-
Dyachok, O.1
Idevall-Hagren, O.2
Sågetorp, J.3
-
67
-
-
0036718447
-
Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism
-
Light PE, Manning Fox JE, Riedel MJ, Wheeler MB. Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism. Mol Endocrinol 2002; 16: 2135-2144.
-
(2002)
Mol Endocrinol
, vol.16
, pp. 2135-2144
-
-
Light, P.E.1
Manning Fox, J.E.2
Riedel, M.J.3
Wheeler, M.B.4
-
68
-
-
50449094096
-
Glucose and GLP-1 stimulate cAMP production via distinct adenylyl cyclases in INS-1E insulinoma cells
-
Ramos LS, Zippin JH, Kamenetsky M, Buck J, Levin LR. Glucose and GLP-1 stimulate cAMP production via distinct adenylyl cyclases in INS-1E insulinoma cells. J Gen Physiol 2008; 132: 329-338.
-
(2008)
J Gen Physiol
, vol.132
, pp. 329-338
-
-
Ramos, L.S.1
Zippin, J.H.2
Kamenetsky, M.3
Buck, J.4
Levin, L.R.5
-
69
-
-
67449092561
-
Enhanced Rap1 activation and insulin secretagogue properties of an acetoxymethyl ester of an Epac-selective cyclic AMP analog in rat INS-1 cells: studies with 8-pCPT-2'-O-Me-cAMP-AM
-
Chepurny OG, Leech CA, Kelley GG et al. Enhanced Rap1 activation and insulin secretagogue properties of an acetoxymethyl ester of an Epac-selective cyclic AMP analog in rat INS-1 cells: studies with 8-pCPT-2'-O-Me-cAMP-AM. J Biol Chem 2009; 284: 10728-10736.
-
(2009)
J Biol Chem
, vol.284
, pp. 10728-10736
-
-
Chepurny, O.G.1
Leech, C.A.2
Kelley, G.G.3
-
70
-
-
31544449107
-
Cyclic AMP/cAMP-GEF pathway amplifies insulin exocytosis induced by Ca2+ and ATP in rat islet β-cells
-
Hashiguchi H, Nakazaki M, Koriyama N, Fukudome M, Aso K, Tei C. Cyclic AMP/cAMP-GEF pathway amplifies insulin exocytosis induced by Ca2+ and ATP in rat islet β-cells. Diabetes Metab Res Rev 2006; 22: 64-71.
-
(2006)
Diabetes Metab Res Rev
, vol.22
, pp. 64-71
-
-
Hashiguchi, H.1
Nakazaki, M.2
Koriyama, N.3
Fukudome, M.4
Aso, K.5
Tei, C.6
-
71
-
-
77349114753
-
Glucose-dependent potentiation of mouse islet insulin secretion by Epac activator 8-pCPT-2'-O-Me-cAMP-AM
-
Kelley GG, Chepurny OG, Schwede F et al. Glucose-dependent potentiation of mouse islet insulin secretion by Epac activator 8-pCPT-2'-O-Me-cAMP-AM. Islets 2009; 1: 260-265.
-
(2009)
Islets
, vol.1
, pp. 260-265
-
-
Kelley, G.G.1
Chepurny, O.G.2
Schwede, F.3
-
73
-
-
0033769693
-
cAMP-GEFII is a direct target of cAMP in regulated exocytosis
-
Ozaki N, Shibasaki T, Kashima Y et al. cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol 2000; 2: 805-811.
-
(2000)
Nat Cell Biol
, vol.2
, pp. 805-811
-
-
Ozaki, N.1
Shibasaki, T.2
Kashima, Y.3
-
76
-
-
0042879894
-
+ channels in pancreatic β cells: role, regulation and potential as therapeutic targets
-
+ channels in pancreatic β cells: role, regulation and potential as therapeutic targets. Diabetologia 2003; 46: 1046-1062.
-
(2003)
Diabetologia
, vol.46
, pp. 1046-1062
-
-
MacDonald, P.E.1
Wheeler, M.B.2
-
78
-
-
0036896712
-
+ currents in β cells: a possible glucose-dependent insulinotropic mechanism
-
+ currents in β cells: a possible glucose-dependent insulinotropic mechanism. Diabetes 2002; 51(Suppl 3): S443-S447.
-
(2002)
Diabetes
, vol.51
, Issue.SUPPL 3
-
-
MacDonald, P.E.1
Salapatek, A.M.2
Wheeler, M.B.3
-
79
-
-
0031965604
-
Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic β cells by both proximal and distal regulatory steps in stimulus-secretion coupling
-
Gromada J, Bokvist K, Ding WG, Holst JJ, Nielsen JH, Rorsman P. Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic β cells by both proximal and distal regulatory steps in stimulus-secretion coupling. Diabetes 1998; 47: 57-65.
-
(1998)
Diabetes
, vol.47
, pp. 57-65
-
-
Gromada, J.1
Bokvist, K.2
Ding, W.G.3
Holst, J.J.4
Nielsen, J.H.5
Rorsman, P.6
-
80
-
-
0033304574
-
Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells
-
Salapatek AM, MacDonald PE, Gaisano HY, Wheeler MB. Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells. Mol Endocrinol 1999; 13: 1305-1317.
-
(1999)
Mol Endocrinol
, vol.13
, pp. 1305-1317
-
-
Salapatek, A.M.1
MacDonald, P.E.2
Gaisano, H.Y.3
Wheeler, M.B.4
-
82
-
-
2642705036
-
A novel lipid-anchored A-kinase anchoring protein facilitates cAMP-responsive membrane events
-
Fraser ID, Tavalin SJ, Lester LB et al. A novel lipid-anchored A-kinase anchoring protein facilitates cAMP-responsive membrane events. EMBO J 1998; 17: 2261-2272.
-
(1998)
EMBO J
, vol.17
, pp. 2261-2272
-
-
Fraser, I.D.1
Tavalin, S.J.2
Lester, L.B.3
-
83
-
-
0031434473
-
Anchoring of protein kinase A facilitates hormone-mediated insulin secretion
-
Lester LB, Langeberg LK, Scott JD. Anchoring of protein kinase A facilitates hormone-mediated insulin secretion. Proc Natl Acad Sci U S A 1997; 94: 14942-14947.
-
(1997)
Proc Natl Acad Sci U S A
, vol.94
, pp. 14942-14947
-
-
Lester, L.B.1
Langeberg, L.K.2
Scott, J.D.3
-
85
-
-
0037232658
-
2+ release in INS-1 pancreatic β cells
-
2+ release in INS-1 pancreatic β cells. J Physiol 2003; 546: 175-189.
-
(2003)
J Physiol
, vol.546
, pp. 175-189
-
-
Kang, G.1
Holz, G.G.2
-
86
-
-
0033829562
-
2+ and electrolyte mobilization following agonist application to the pancreatic β cell line HIT
-
2+ and electrolyte mobilization following agonist application to the pancreatic β cell line HIT. Pflugers Arch 2000; 440: 828-834.
-
(2000)
Pflugers Arch
, vol.440
, pp. 828-834
-
-
Nakagaki, I.1
Sasaki, S.2
Hori, S.3
Kondo, H.4
-
92
-
-
0030792753
-
Protein kinase A-dependent and -independent stimulation of exocytosis by cAMP in mouse pancreatic B-cells
-
Renström E, Eliasson L, Rorsman P. Protein kinase A-dependent and -independent stimulation of exocytosis by cAMP in mouse pancreatic B-cells. J Physiol 1997; 502(Pt 1): 105-118.
-
(1997)
J Physiol
, vol.502
, Issue.PART 1
, pp. 105-118
-
-
Renström, E.1
Eliasson, L.2
Rorsman, P.3
-
93
-
-
0037337832
-
SUR1 regulates PKA-independent cAMP-induced granule priming in mouse pancreatic B-cells
-
Eliasson L, Ma X, Renström E et al. SUR1 regulates PKA-independent cAMP-induced granule priming in mouse pancreatic B-cells. J Gen Physiol 2003; 121: 181-197.
-
(2003)
J Gen Physiol
, vol.121
, pp. 181-197
-
-
Eliasson, L.1
Ma, X.2
Renström, E.3
-
94
-
-
0037103455
-
Synergistic effect of dimethyl sulfoxide on glucagon-like peptide 1 (GLP-1)-stimulated insulin secretion and gene transcription in INS-1 cells: characterization and implications
-
Kemp DM, Habener JF. Synergistic effect of dimethyl sulfoxide on glucagon-like peptide 1 (GLP-1)-stimulated insulin secretion and gene transcription in INS-1 cells: characterization and implications. Biochem Pharmacol 2002; 64: 689-697.
-
(2002)
Biochem Pharmacol
, vol.64
, pp. 689-697
-
-
Kemp, D.M.1
Habener, J.F.2
-
95
-
-
67649666737
-
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
-
Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47.
-
(2009)
Lancet
, vol.374
, pp. 39-47
-
-
Buse, J.B.1
Rosenstock, J.2
Sesti, G.3
-
96
-
-
33847021177
-
Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1
-
de Heer J, Holst JJ. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes 2007; 56: 438-443.
-
(2007)
Diabetes
, vol.56
, pp. 438-443
-
-
de Heer, J.1
Holst, J.J.2
-
97
-
-
67650490677
-
Exenatide exhibits dose-dependent effects on glycemic control over 12weeks in Japanese patients with suboptimally controlled type 2 diabetes
-
Kadowaki T, Namba M, Yamamura A, Sowa H, Wolka AM, Brodows RG. Exenatide exhibits dose-dependent effects on glycemic control over 12weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocr J 2009; 56: 415-424.
-
(2009)
Endocr J
, vol.56
, pp. 415-424
-
-
Kadowaki, T.1
Namba, M.2
Yamamura, A.3
Sowa, H.4
Wolka, A.M.5
Brodows, R.G.6
|